Poor
Mostly Aligned
Patient Risk:
Low
Summary
Only one claim (Dupixent is a biologic monoclonal antibody) is supported by the label excerpt; the remaining claims pertain to patents, biosimilars, pricing, and litigation not present in the provided prescribing information, resulting in overall poor alignment.
Category Scores
Accurate Statements
Dupixent is a biologic monoclonal antibody.
12.1
Unsupported Statements
There will be no generic version of Dupixent (dupilumab) available in 2026.
Not supported by the provided prescribing information excerpt.
Generics are not possible for Dupixent.
Not supported by the provided prescribing information excerpt.
Biosimilars would compete after patents expire.
Not supported by the provided prescribing information excerpt.
Key U.S. patents protecting Dupixent extend beyond 2026, blocking any biosimilar entry that year.
Not supported by the provided prescribing information excerpt.
Primary U.S. composition-of-matter patents for Dupixent expire in 2031.
Not supported by the provided prescribing information excerpt.
Method-of-use patents last until 2033–2038.
Not supported by the provided prescribing information excerpt.
Pediatric exclusivity could push this to 2034.
Not supported by the provided prescribing information excerpt.
No major patents lapse in 2026.
Not supported by the provided prescribing information excerpt.
No approved or pending biosimilars target a 2026 U.S. launch.
Not supported by the provided prescribing information excerpt.
Alvotech, Intas, and Celltrion have filed abbreviated biologics license applications (aBLAs).
Not supported by the provided prescribing information excerpt.
FDA reviews delay launches until at least 2031–2032.
Not supported by the provided prescribing information excerpt.
European biosimilars from Biocon and Lupin launched in 2025.
Not supported by the provided prescribing information excerpt.
U.S. entry faces separate patent litigation.
Not supported by the provided prescribing information excerpt.
Sanofi and Regeneron hold over 20 Orange Book-listed patents.
Not supported by the provided prescribing information excerpt.
These include formulation patents extended via pediatric studies.
Not supported by the provided prescribing information excerpt.
Ongoing lawsuits against Samsung Bioepis reinforce exclusivity.
Not supported by the provided prescribing information excerpt.
Dupixent generated $12.7 billion in 2024 sales.
Not supported by the provided prescribing information excerpt.
Biosimilar makers can challenge via FDA's 351(k) pathway.
Not supported by the provided prescribing information excerpt.
Settlements often delay entry, e.g., 2031 carve-outs.
Not supported by the provided prescribing information excerpt.
A rare early win could allow a limited U.S. launch pre-2031.
Not supported by the provided prescribing information excerpt.
As of 2025, no ruling allowing a limited U.S. launch before 2031 exists for Dupixent.
Not supported by the provided prescribing information excerpt.
The annual U.S. list price exceeds $40,000 per patient.
Not supported by the provided prescribing information excerpt.
No generics or biosimilars mean high costs through 2030.
Not supported by the provided prescribing information excerpt.
Sanofi patient assistance programs cover copays for eligible insured patients.
Not supported by the provided prescribing information excerpt.
Off-label alternatives like JAK inhibitors (e.g., generic tofacitinib) treat some indications cheaper but lack direct comparability.
Not supported by the provided prescribing information excerpt.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Label excerpt contains only Mechanism of Action (12.1). No on-label indications, dosing, contraindications, warnings, adverse reactions, or other standard labeling sections are provided for evaluation.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Evaluation is based on patent and market-entry claims, not patient safety data; no safety claims are supported by the label excerpt provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Label content is extremely limited (12.1 MOA only). The evaluation treats patent/biosimilar discussions as on-label content, which is not supported by the label excerpt.
Suggested Improvement
Provide the full prescribing information (indications, dosing, contraindications, warnings, adverse events, interactions, and use in specific populations) to enable accurate alignment assessment; separate on-label content from off-label/patent-related content.